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Dear Editor,
Hardly any topic in modern critical
care medicine remains as controver-
sial as steroid administration in acute
respiratory distress syndrome
(ARDS), despite multiple adult ran-
domized controlled trials (RCTs) and
recent pediatric data. The article by
Yehya et al. [1] and the editorial
commentary by Peters et al. [2] are
vital, since few, if any, therapeutic
approaches are simultaneously asso-
ciated with such profound potential
benefits and risks as steroid therapy in
critically ill patients.
Marked contradiction, however,
exists between the Yehya et al. data
and the findings of well-designed and
protocol-driven RCTs in adult ARDS
patients. These studies consistently
reported significant improvements in
markers of systemic inflammation,
ventilator-free days, ICU-free days,
no changes or actually improved
survival, and either no increase or
decreases in infection rate [3, 4]. The
findings of Yehya et al. cannot be
interpreted because the specific indi-
cations for corticosteroid use were not
reported. To imply that any type of
steroid, at any concentration, and
used for more than 24 h represents a
protocol-driven treatment for pedi-
atric ARDS (PARDS) is simply not
justifiable.
Further, grouping short-term (less
than 24 h) and non-corticosteroid
exposed patients together is an
improper control for evaluating ster-
oid therapy. Corticosteroids can exert
important, non-genomic effects
within minutes, including decreased
cell adhesion, phosphokinase activa-
tion, MCP-1 and H2O2 release, CD63
translocation, TNF-a and IL-6
expression. Possible corticosteroid
effects cannot be assessed unless
exposed and non-exposed patients are
categorically separated. Thus,
proposing that this single-center,
observational study ‘‘has relevance
for clinical practice’’, a conclusion
unsupported by data, will likely mis-
lead and confound many bedside
physicians. Undoubtedly, the most
likely explanation for Yehya et al.’s
findings are (1) selection of steroid
therapy for the sickest patients (con-
founding by indication) and (2)
rebound effects resulting from abrupt
discontinuation of corticosteroids, as
is well documented by worsening
PaO2/FiO2 ratios and increasing CRP
levels.
Owing to the wide-ranging impli-
cations and inherent responsibility of
publishing patient data, it is impera-
tive that we treat this topic with the
utmost equipoise until clear evidence
for or against steroid use in ARDS/
PARDS is gained. Whether compar-
ative effectiveness research (CER)
can provide such evidence is ques-
tionable, since the US Food and Drug
Administration, European Medicines
Agency, or other labeling agencies do
not consider this research methodol-
ogy Level 1 evidence. CER studies
can ‘‘adjust’’ the outcomes for
measured confounders, and boot-
strapping techniques like propensity
scoring can reduce the margin of
inferential errors, but only large, well-
designed RCTs can control for
unmeasured and non-measurable
confounders. We recommend caution
in drawing conclusions from a data
set with multiple confounding vari-
ables and improper controls.
Statistical approaches such as
propensity score matching can only
take into account measured con-
founding factors, whereas
randomized trials allow for control-
ling of both measured and
unmeasured confounders. The bene-
ficial or no-harm results reported in
adult RCTs cannot be disregarded
unless systematically investigated in
pediatric patients. We recently pub-
lished a feasibility RCT investigating
prolonged low-dose methylpred-
nisolone in pediatric ARDS [5] and,
undoubtedly, there is an urgent need
to conduct a large-scale, well-de-
signed RCT in PARDS.
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